EFSA Issues Positive Opinion to Limicol Claim

NANTES, France Laboratoire Lescuyer successfully obtained a positive opinion on a health claim under Article 14 for a food supplement Limicol from the European Food Safety Authority (EFSA) Nutrition, Dietetic product and Allergies (NDA) panel.

With support from contract research company Biofortis, the product has five years of research and three clinical trials to scientifically back its benefits in reducing LDL cholesterol. According to Biofortis, only 16 Article 14 health claims had previously received a positive opinion from EFSA for adult nutritional products in Europe, and the first time a food supplement dossier with data protection received a positive assessment from EFSA regarding a disease risk reduction claim.

We are confident that this success will motivate new players in targeting EFSA claims with a new and proven methodology," said Murielle Cazaubiel, head of Biofortis Clinical.